The Technical Analyst
Select Language :
Vericel Corp [VCEL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Vericel Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Vericel Corp is listed at the  Exchange

5.59% $52.33

America/New_York / 27 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 2 527.03 mill
EPS: -0.0700
P/E: -747.57
Earnings Date: May 07, 2024
SharesOutstanding: 48.29 mill
Avg Daily Volume: 0.594 mill
RATING 2024-03-27
S-
Strong Buy
RATINGS
Rating CashFlow: Neutral
Return On Equity: Buy
Return On Asset: Strong Buy
DE: Buy
P/E: Strong Buy
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -747.57 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-127.17x
Company: PE -747.57 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$3.75
(-92.83%) $-48.58
Date: 2024-03-28
Expected Trading Range (DAY)

$ 50.54 - 54.12

( +/- 3.41%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-13 Colangelo Dominick Buy 17 500 Stock Option (Right to Buy)
2024-03-14 Colangelo Dominick Buy 17 500 Stock Option (Right to Buy)
2024-03-14 Colangelo Dominick Buy 17 500 Common Stock
2024-03-14 Colangelo Dominick Sell 17 500 Common Stock
2024-03-13 Colangelo Dominick Sell 17 500 Common Stock
INSIDER POWER
65.48
Last 98 transactions
Buy: 831 070 | Sell: 174 197

Forecast: 16:00 - $52.33

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $52.33
Forecast 2: 16:00 - $52.33
Forecast 3: 16:00 - $52.33
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $52.33 (5.59% )
Volume 0.554 mill
Avg. Vol. 0.594 mill
% of Avg. Vol 93.22 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Vericel Corp

Last 12 Months

Last 12 months chart data with high, low, open and close for Vericel Corp

RSI

Intraday RSI14 chart for Vericel Corp

Last 10 Buy & Sell Signals For VCEL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$45.62N/AActive
Profile picture for
            Vericel Corp

VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date Signal @
MUSEUSDMar 28 - 05:3119.59
AXSUSDMar 28 - 05:33$11.25
KNCUSDMar 28 - 05:31$0.912
MNTUSDMar 28 - 05:291.200
BANDUSDMar 28 - 05:30$2.14
DPXUSDMar 28 - 05:2841.81
BNBXUSDMar 28 - 05:28635.66
WANETHUSDMar 28 - 05:243 559.88
TONUSDMar 28 - 05:234.93
THETAUSDMar 28 - 05:24$2.98

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.